WHO ICTRP trial
A clinical trial evaluating vildagliptin and nilotinib as a combination…
EUCTR2017-000899-28-NL · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2017-000899-28-NL |
|---|---|
| Public title | A clinical trial evaluating vildagliptin and nilotinib as a combination treatment to achieve and succesfully maintain treatment free remission in patients with chronic myeloid leukemia. |
| Scientific title | Dipeptidylpeptidase IV (CD26) on Philadelphia-positive leukemic stem cells (LSC) as marker and novel therapeutic target in chronic myeloid leukemia (CML). - Dolphin-STAR |
| Primary sponsor | Albert Schweitzer Hospital |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): yes Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | Netherlands |
| Conditions | Chronic myeloid leukemia MedDRA version: 21.1 Level: LLT Classification code 10009015 Term: Chronic myeloid leukemia System Organ Class: 100000004864 MedDRA version: 21.0 Level: LLT Classification code 10009016 Term: Chronic myeloid… |
| Interventions | Trade Name: Tasigna Product Name: Nilotinib Product Code: AMN107 Pharmaceutical Form: Capsule Trade Name: Galvus Product Name: Vildaglipitin Pharmaceutical Form: Tablet |
| Registration date | Nov 15, 2017 |
| Target size | 20 |
| Secondary IDs | CAMN107CNL08T |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: